Quantcast

Latest Dendreon Stories

2011-05-16 13:50:00

MAYWOOD, N.J., May 16, 2011 /PRNewswire/ -- New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone...

2011-05-02 15:00:00

SEATTLE, May 2, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2011. Revenue for the quarter ended March 31, 2011 was $28.1 million compared to $21,000 for the quarter ended March 31, 2010. The GAAP net loss for the quarter ended March 31, 2011 was $111.8 million, or $0.77 per share, compared to $125.7 million, or $0.96 per share for the quarter ended March 31, 2010 (which included a non-cash charge of $68 million...

2011-04-29 08:00:00

VANCOUVER, British Columbia, April 29, 2011 /PRNewswire-Asia/ -- Insiderslab.com issues new research reports that highlight large insider trade found in for Micron, AT&T, Discovery, Apple, Amarin, & Dendreon. Read our research reports with Interactive Insider Trading Charts and Insider Trade Statistics below. How do investors start narrowing down their investment choices? People might have opportunities to invest their money into more than thousands of stocks every day. However,...

2011-04-28 05:00:00

SEATTLE, April 28, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: Deutsche Bank Annual Health Care Conference, Boston, MA on May 4, 2011 at 8:40 a.m. ET Bank of America Merrill Lynch Health Care Conference, Las Vegas, NV on May 10, 2011 at 8:40 a.m. PT The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live...

2011-04-20 08:15:00

SAN FRANCISCO, April 20, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) ("the Company")and maintains its twelve month target price of $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "According to the Company, Opexa's lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is scheduled to advance into a pivotal Phase 3 clinical...

2011-04-14 05:00:00

SEATTLE, April 14, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, May 2, 2011 at 4:30 p.m. ET to review the first quarter 2011 financial results. Access to the discussion may be obtained as follows: Time: 4:30 PM ET / 1:30 PM PT Date: May 2, 2011 1-877-548-9590 (domestic) or +1-720-545-0037 Dial-in: (international); conference pass code:...

2011-04-06 07:00:00

SEATTLE, April 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida: Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET. "B lymphocytes are activated during the course of sipuleucel-T treatment, leading to an antigen-specific humoral response." Poster presentation. Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET....

2011-04-02 00:00:28

New advances in treatment for prostate disease are a chief focus of Harvard Medical School's 2011 Annual Report on Prostate Diseases. Boston, MA (Vocus/PRWEB) April 01, 2011 New advances in treatment for prostate disease are a chief focus of Harvard Medical School's 2011 Annual Report on Prostate Diseases. "All of these advances may change the way men with prostate disease are treated right now or in the near future," says Dr. Marc Garnick, editor in chief of the report. "While many of...

2011-03-30 17:35:00

SEATTLE, March 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued a proposed decision memo for PROVENGE® (sipuleucel-T). Dendreon appreciates the work and diligent scientific review conducted by CMS that resulted in the draft decision memo, in which CMS proposes that the evidence is adequate to conclude that the use of autologous cellular immunotherapy with PROVENGE improves...

2011-03-22 15:15:00

NEW YORK, March 22, 2011 /PRNewswire/ -- A study in the prostate cancer space completed this week by ITG's Majestic Market Research reveals that Amgen's (Nasdaq: AMGN) Xgeva (a.k.a. denosumab, Prolia) is on track to achieve its blockbuster sales potential and is already stealing share from the leading agent for skeletal related events, Novartis' (NYSE: NVS) Zometa. As for Dendreon's (Nasdaq: DNDN) Provenge, the first FDA-approved therapeutic cancer vaccine, physicians are still clouded...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.
Related